

Ref. No: 687
From: Research
Date: 03/05/23
Subject: Biologic medicines in Dermatology

REQUEST

I have a Freedom of Information query regarding the use of biologic medicines in Dermatology. Could you please answer the following two questions:

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Apremilast
 - Bimekizumab
 - Brodalumab
 - Certolizumab
 - Deucravacitinib
 - Dimethyl fumarate
 - Etanercept - Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Tildrakizumab
 - Ustekinumab
2. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Secukinumab
 - Ustekinumab
3. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:
 - Ciclosporin
 - Methotrexate - any form and strength
 - Methotrexate injections 15mg and above

RESPONSE

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Data: 1st February 2023 – 1st May 2023

Drug	Patients
Adalimumab - Humira	9
Adalimumab Biosimilar	47
Apremilast	58
Bimekizumab	0
Brodalumab	0
Certolizumab	<5
Deucravacitinib	0
Dimethyl fumarate	6
Etanercept - Enbrel	0
Etanercept Biosimilar	<5
Guselkumab	8
Infliximab - Remicade	0
Infliximab Biosimilar	0
Ixekizumab	<5
Risankizumab	<5
Secukinumab	<5
Tildrakizumab	0
Ustekinumab	20

2. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:

Section 12: cost of compliance exceeds the appropriate limit

The Trust would need to undertake a manual review of patient records to provide an answer to the remaining questions, as we do not centrally record the indication being treated. Under Section 12 of the Freedom of Information Act, St Helens & Knowsley Teaching Hospitals NHS Trust does not have to comply with a request where we estimate that the cost of compliance would exceed the appropriate limit of £450. The appropriate limit has been specified within the regulations and represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions.

3. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

Please refer to question two.